- Home
- TSBK vs CLLS Comparison
TSBK vs CLLS Comparison
Compare TSBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBK
- CLLS
- Stock Information
- Founded
- TSBK 1915
- CLLS 1999
- Country
- TSBK United States
- CLLS France
- Employees
- TSBK N/A
- CLLS N/A
- Industry
- TSBK Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TSBK Finance
- CLLS Health Care
- Exchange
- TSBK Nasdaq
- CLLS Nasdaq
- Market Cap
- TSBK 229.3M
- CLLS 240.2M
- IPO Year
- TSBK 1998
- CLLS 2007
- Fundamental
- Price
- TSBK $31.11
- CLLS $1.91
- Analyst Decision
- TSBK
- CLLS Buy
- Analyst Count
- TSBK 0
- CLLS 2
- Target Price
- TSBK N/A
- CLLS $8.00
- AVG Volume (30 Days)
- TSBK 13.4K
- CLLS 22.5K
- Earning Date
- TSBK 10-28-2024
- CLLS 11-04-2024
- Dividend Yield
- TSBK 3.15%
- CLLS N/A
- EPS Growth
- TSBK N/A
- CLLS N/A
- EPS
- TSBK 3.03
- CLLS N/A
- Revenue
- TSBK $74,387,000.00
- CLLS $19,635,000.00
- Revenue This Year
- TSBK N/A
- CLLS $271.02
- Revenue Next Year
- TSBK N/A
- CLLS $33.48
- P/E Ratio
- TSBK $9.91
- CLLS N/A
- Revenue Growth
- TSBK N/A
- CLLS N/A
- 52 Week Low
- TSBK $23.93
- CLLS $0.96
- 52 Week High
- TSBK $32.24
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- TSBK 55.48
- CLLS 37.89
- Support Level
- TSBK $28.75
- CLLS $1.95
- Resistance Level
- TSBK $30.59
- CLLS $2.04
- Average True Range (ATR)
- TSBK 0.62
- CLLS 0.09
- MACD
- TSBK 0.03
- CLLS -0.01
- Stochastic Oscillator
- TSBK 76.38
- CLLS 18.92
About TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. Company also offers loans to real estate, including residential and commercial / multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans and land loans. The company mainly operates in the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.